IBJNews

Pace of life sciences venture capital deals in Indiana picks up

Back to TopCommentsE-mailPrintBookmark and Share
On The Beat Industry News In Brief

After no Indiana health and life sciences firms announced venture capital deals in the second quarter, five did so in the third, and two more have already this month.

That’s equal to the number of companies attracting investment in the first quarter, but the value per deal grew from more than $4 million to more than $5 million, according to data from BioEnterprise, a Cleveland-based life sciences business development group.

The companies securing investments in the third quarter were Dormir LLC, Carmel, an operator of sleep centers: $12 million; Nico Corp., Indianapolis, a developer of technology for minimally invasive neurosurgery: $10 million; Diagnostic ID, Indianapolis, a maker of a system that matches patients with their biopsy samples: $3 million; Matrix-Bio, West Lafayette, a maker of a blood test for early-stage detection of breast cancer: $200,000; and FAST Diagnostics, Indianapolis, a maker of a kidney filtering monitor: $150,000.

In October, Warsaw-based OrthoPediatrics shared an undisclosed portion of $1.4 million handed out by StepStone Angels, an Indianapolis-based group of private investors. Also, West Lafayette-based developer of cancer drugs Endocyte Inc. pulled in a whopping $26 million from its investors.

Even with that deal, the average size of investment is about half what it was a year ago, and even less than in 2007, before the recession took hold.

Health-care-related venture capital deals in other Midwestern states have also increased in number this year, but decreased in size, according to BioEnterprise.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
thisissue1-092914.jpg 092914

Subscribe to IBJ
ADVERTISEMENT